Poxel S.A.
PAR: POXEL.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicolas Trouche
- Employees
- 6
- Headquarters
- Lyon, France
- IPO year
- 2015
- Market cap
- €13.9M
- Website
- https://www.poxelpharma.com
Loading POXEL…
Loading profile data…Frequently asked questions about POXEL
What does Poxel S.A. (POXEL.PA) do?
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of...
Where does POXEL.PA trade?
Poxel S.A. (POXEL.PA) trades on the Euronext Paris.
What sector is POXEL.PA in?
Poxel S.A. (POXEL.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Poxel S.A.?
Nicolas Trouche is the chief executive officer of Poxel S.A. (POXEL.PA).
Where is Poxel S.A. headquartered?
Poxel S.A. is headquartered in France.
Does POXEL.PA pay a dividend?
Poxel S.A. (POXEL.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did POXEL.PA go public?
Poxel S.A. (POXEL.PA) completed its initial public offering in 2015.